Psyence Biomedical Ltd. (PBM)
- Previous Close
0.5299 - Open
0.5008 - Bid 0.4189 x 100
- Ask 0.5078 x 100
- Day's Range
0.4202 - 0.5010 - 52 Week Range
0.3670 - 108.0000 - Volume
168,792 - Avg. Volume
241,522 - Market Cap (intraday)
2.066M - Beta (5Y Monthly) -0.13
- PE Ratio (TTM)
-- - EPS (TTM)
-76.9100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
www.psyencebiomed.comRecent News: PBM
View More
Performance Overview: PBM
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PBM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PBM
View MoreValuation Measures
Market Cap
2.07M
Enterprise Value
2.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-137.79%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-46.59M
Diluted EPS (ttm)
-76.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.93M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-395.83k